Evidence map›Paper›PMID 41448279›Full record

ArticleNeurotoxicology2026

Power calculations for larval zebrafish in light-dark transition test for developmental neurotoxicity.

Kathryn S Konrad, Katherine Allen-Moyer, Lee Ellis, Ellen Hessel, Oihane Jaka, Arantza Muriana, Beatriz Molina Martínez, Ana Del Pozo, Valentina Schiavone, Vincenzo Di Donato and 6 more

Abstract read
In one paragraph

Article in Neurotoxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Formononetin attenuates glucocorticoid-induced osteoporosis via multiple osteoimmunological pathways: evidence from zebrafish and network pharmacology.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kathryn S KonradDLH, LLC, Bethesda, MD, USA.
Katherine Allen-MoyerDLH, LLC, Bethesda, MD, USA.
Lee EllisNational Research Council of Canada, Halifax, NS, Canada.
Ellen HesselCentre for Health Protection, National Institute for Public Health and the Environment, Utrecht, the Netherlands.
Oihane JakaBBD BioPhenix SLU - Biobide, San Sebastian, Gipuzkoa, Spain.
Arantza MurianaBBD BioPhenix SLU - Biobide, San Sebastian, Gipuzkoa, Spain.
Beatriz Molina MartínezBBD BioPhenix SLU - Biobide, San Sebastian, Gipuzkoa, Spain.
Ana Del PozoBBD BioPhenix SLU - Biobide, San Sebastian, Gipuzkoa, Spain.
Valentina SchiavoneZeClinics SL, Barcelona, Spain.
Vincenzo Di DonatoZeClinics SL, Barcelona, Spain.
Claudia Miguel SanzZeClinics SL, Barcelona, Spain.
Lisa TruongDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Robyn TanguayDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
Keith R ShockleyDivision of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
Kristen RyanDivision of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
Jui-Hua HsiehDivision of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA. Electronic address: jui-hua.hsieh@nih.gov.

Funding

Developmental Neurotoxicity Health Effects Innovation Research ProgramZIAES103387 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MCPHERSON, CHRISTOPHER ANTHONY · 2022 to 2025
$5.2M
Intramural NIH HHS Z99 ES999999Intramural NIH HHS ZIA ES103387
6 · The paper itself

Abstract

The link between environmental chemical exposures and neurodevelopmental disorders such as autism and attention-deficit/hyperactivity disorder underscores the need to develop efficient developmental neurotoxicity (DNT) assays for chemical evaluation. The zebrafish Light-Dark Transition Test (LDTT) assesses changes in zebrafish larval behavioral responses to chemical exposure by recording their distance moved under alternating light and dark conditions. To gain confidence in classifying a chemical as having a DNT effect for the LDTT assay, it is important to determine the minimum sample size to obtain a robust behavioral response. We calculated statistical power under common models based on LDTT data collected from four laboratories using standard protocol parameters, where each 96-well plate contained 5-7 test concentrations and 12-16 vehicle control wells (1 larva/well). Power calculations were conducted to identify concentration effects using t-tests, analysis of variance (ANOVA), and repeated measures ANOVA (RMANOVA), with data from four endpoints: Total Distance, Movement Similarity, Distance Change, and Distance Shift. The tests showed the highest power for the Movement Similarity and Distance Change endpoints, which had the lowest intra- and inter-laboratory variability, resulting in a smaller necessary sample size to estimate dose effects. The use of these endpoints more than doubled the power of the statistical tests for the Total Distance endpoints using the same sample size and typically required between 8 and 32 samples to achieve 80 % power at a 20 % effect size. This work demonstrates that the LDTT can be improved for detecting DNT effects by careful consideration of endpoint selection, data transformation, and type of statistical test.

Indexed as

Behavior, AnimalNeurotoxicity SyndromesToxicity TestsZebrafishAnimalsDose-Response Relationship, DrugLarvaMotor ActivityDevelopmental Neurotoxicity (DNT)Light-Dark Transition Test (LDTT)New Approach Methodologies (NAMs)Power Analysis and CalculationsReproducibilityZebrafish

Identifiers

PMID41448279
PMCPMC12776591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.